Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
DOI:
https://doi.org/10.12775/JEHS.2020.10.09.034Keywords
mantle cell lymphoma, ibrutinib, maintenance therapyAbstract
Mantle cell lymphoma is a rare subtype of non- Hodgkin lymphoma with life-threatening course of disease. It mostly affects older adults in their sixth or seventh decade of life with male to female predominance of 3 to 1. It prognosis is very poor and the treatment is demanding. The golden standard therapy for younger, fit patients <65 years is chemoimmunotherapy such as R-CHOP/R-DHAP rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisolone, dexamethasone, cytarabine and cisplatin) followed by BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan) and autologous- stem-cell transplant (ASCT). Nevertheless MCL is mainly recognized in patients of average age 67 in whom comorbidities often play a crucial role during treatment.
A 56- years old patient was admitted to the Department of Hematooncology and Bone Marrow Transplantation with clinical symptoms such as heavy night sweats, generalized enlargement of lymph nodes, massive weight loss, dyspnea and fatigue. Initial physical examination and imaging showed enormous hepatosplenomegaly, mass in the lungs and fluid in the pleural cavity.
The patients underwent chemioimmunotherapy consolidated with an autologous stem cell transplant. To date, the patient is on maintenance treatment with ibrutinib.
References
Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647-1656. doi:10.1182/blood-2018-03-791392
Parrott M, Rule S. Does maintenance therapy have a role in mantle cell lymphoma treatment?. Expert Rev Hematol. 2018;11(4):285-292. doi:10.1080/17474086.2018.1449635
Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181(5):703-706. doi:10.1111/bjh.14699
Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantlecell lymphoma. N Engl J Med. 2017;377:1250–1260
Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121:48–53
Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–5675
Brian G, Till MD. Maintance therapy in diffuse large B-cell lymphoma and mantle cell lymphoma. Curr Treat Options in Oncol. 2018; 19-45
Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1995;13:2819–2826
Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705–711
Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–4008
Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–531
Ahmadi T, McQuade J, Porter D, et al. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant. 2012;47:1082–1086.
Graf SA, Stevenson PA, Holmberg LA, et al. Maintenance rituximab afterautologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol. 2015;26:2323–2328.
Mei MG, Cao TM, Chen L, et al. Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab. Biol Blood Marrow Transplant. 2017;23:1861–1869
Barth MJ, Mavis C, Czuczman MS, et al. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma. Clin. Cancer Res. 2015, 21: 4391–4397
Heinrich DA, Weinkauf M, Hutter G, et al. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma. Br. J. Haematol. 2015, 168: 606–610
Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (ga101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: Results from the phase II gauguin study. J. Clin. Oncol. 2013, 31: 2912–2919
Furtado M, Dyer MJ, Johnson R, et al. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma—A phase II trial. Br. J. Haematol. 2014, 165: 575–578
Mondello P, Steiner N, Willenbacher W, et. al. 90y-ibritumomab-tiuxetan consolidation therapy for advanced-stage mantle cell lymphoma after first-line autologous stem cell transplantation: Is it time for a step forward? Clin. Lymphoma Myeloma Leuk. 2016, 16: 82–88
Kaplan LD. Jung SH. Stock W. Bartlett, et al. Bortezomib maintenance (bm) versus consolidation (bc) following aggressive immunochemotherapy and autologous stem cell transplant (asct) for untreated mantle cell lymphoma (mcl): Calgb (alliance) 50403. Blood 2015, 126, 337.
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516
Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016; 387: 770–778.
Skarzynski M, Niemann CU, Lee YS, et al. Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res 2016; 22: 86–95
Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123: 1957–1960
Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet 2018;5: 109-116
Yan F, Gopal AK, Graf S. Targeted drugs as maintenance therapy after autologous stem cell transplantation in patients with mantle cell lymphoma. Pharmaceuticals 2017, 10: 1-11.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 617
Number of citations: 0
